Home / News / News and information / Kexing Biopharm...

Kexing Biopharm's Product Introduction

Article source：Kexing Biopharm

Jun 17,2025

View： 1791

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

Kexing Biopharm's Product Introduction

LABEL:

Related News

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

Kexing Biopharm Introduces Eribulin Mesylate Injection, Expanding Its Overseas Product Portfolio

Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone

Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone

Harnessing the Power of Recombinant Collagen Repair Mask for Youthful Skin

Harnessing the Power of Recombinant Collagen Repair Mask for Youthful Skin

Shanghai Securities News' "Innovation China" visits Kexing Biopharm

Shanghai Securities News' "Innovation China" visits Kexing Biopharm

Kexing Biopharm Granted Exclusive Commercialization License for Overseas Marketing of TOT BIOPHARM's Bevacizumab

Kexing Biopharm Granted Exclusive Commercialization License for Overseas Marketing of TOT BIOPHARM's Bevacizumab

China's first infliximab biosimilar drug ready for export, Kexing Biopharm initiated drug registration in 17 countries

China's first infliximab biosimilar drug ready for export, Kexing Biopharm initiated drug registration in 17 countries